Clinical Trial Update: Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the combination of Fulvestrant with Lu-DOTATATE for metastatic pancreatic neuroendocrine tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Fulvestrant (fulvestrant)
• Lu-DOTATATE (Lutetium-177 DOTATATE)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Pancreatic Neuroendocrine Tumor | Phase 1 | Status: RECRUITING